SynthesisArthritis research & therapy2018
The prevalence of depression in axial spondyloarthritis and its association with disease activity: a systematic review and meta-analysis.
Synthesis in Arthritis research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 4 syntheses or guidelines pooled it, 146 citations in OpenAlex.
- Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis.Rheumatology (Oxford, England) · 2020Pooled it
- The prevalence and impact of depression in primary systemic vasculitis: a systematic review and meta-analysis.Rheumatology international · 2020Pooled it
- Systematic review of mental health comorbidities in psoriatic arthritis.Clinical rheumatology · 2020Pooled it
- Prevalence of depression in SARS-CoV-2 infected patients: An umbrella review of meta-analyses.General hospital psychiatryPooled it
- The effects of WeChat-based educational intervention in patients with ankylosing spondylitis: a randomized controlled trail.Arthritis research & therapy · 2021Trial
- Infliximab treatment reduces depressive symptoms in patients with ankylosing spondylitis: an ancillary study to a randomized controlled trial (ASSERT).Arthritis research & therapy · 2020Trial
- Patient and physician global assessments capture distinct clinical domains in axial spondyloarthritis.Clinical rheumatology · 2026Article
- Effects of neuroinflammation and neurotrophic factors on mental health of people with axial spondyloarthritis.Brain, behavior, & immunity - health · 2026Article
- Underrecognized depressive and anxiety symptoms in inflammatory arthritis: implications for systematic screening using PHQ-9 and GAD-7.Rheumatology international · 2026Observational
- Article
- Treatment Adherence, Psychosocial Factors, and Clinical Outcomes in Repeatedly Hospitalized Patients with Rheumatoid Arthritis and Ankylosing Spondylitis: An Exploratory Mid-Term Longitudinal Mixed-Effects Study.Medical sciences (Basel, Switzerland) · 2026Observational
- Association of inflammation and serum adipocytokines with depression and anxiety burden in axial spondyloarthritis.Scientific reports · 2026Article
- Clinical characteristics, disease activity and psychosocial burden of axial spondyloarthritis in Jordan: a multicenter cross-sectional study.Scientific reports · 2026Observational
- Diagnostic Accuracy of Interleukin-17A for Internal Derangements of Temporomandibular Joints in Patients with Spondyloarthritis.Biomedicines · 2026Article
- Associations Between Depression and Reduced Quality of Life in Women with Non-Radiographic Axial Spondyloarthritis: A Cross-Sectional Study.Biomedicines · 2026Article
- Disease activity and mental health symptoms in axial spondyloarthritis: concordant or discordant?Rheumatology (Oxford, England) · 2026Article
- Impact Of A Structured Emotional Well-Being Workshop On Psychological Outcomes And Patient Activation In Rheumatoid Arthritis And Spondyloarthritis: A Pilot Study.Journal of multidisciplinary healthcare · 2026Article
- Impact of interventions to prevent anxiety and depression in people with inflammatory rheumatological conditions: a systematic review.Rheumatology advances in practice · 2026Review
- Risk of anxiety disorder following ankylosing spondylitis, 2012-2023: a nationwide cohort study in South Korea.Frontiers in psychiatry · 2026Article
- Psychological distress differentiates subjective health within a vulnerable subgroup of patients with immune-mediated inflammatory diseases.Frontiers in psychology · 2026Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDepression is common among patients with axial spondyloarthritis (axSpA), but reports of its prevalence are highly variable. We performed a systematic review to (i) describe the prevalence of depression in axSpA, (ii) compare its prevalence between axSpA, ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA) cohorts, and (iii) compare disease activity and functional impairment between those with and without depression.
methodsWe searched Medline, PubMed, Web of Science, PsycINFO, CINAHL Plus, the Cochrane library and conference abstracts of the European League Against Rheumatism, British Society for Rheumatology and American College of Rheumatology using a predefined protocol in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Meta-analysis was performed using quality-effects model.
resultsFifteen original articles and one abstract were included for analysis; 14 studies described AS cohorts and two nr-axSpA. Three screening criteria and one diagnostic criterion were used to define depression. Prevalence ranged from 11 to 64% depending on criteria and thresholds used. Pooled prevalence of at least moderate depression was 15% using the Hospital Anxiety and Depression Scale (HADS) threshold of ≥ 11. The prevalence of depression was similar between axSpA, AS and nr-axSpA cohorts. Patients with depression had significantly worse disease activity, including higher BASDAI by 1.4 units (95% CI 1.0 to 1.9), ASDAS by 0.5 units (95% CI 0.3 to 0.7) and ESR by 3.5 mm/h (95% CI 0.6 to 6.4). They also had greater functional impairment with higher BASFI and BASMI by 1.2 units (95% CI 0.6 to 1.8) and 0.6 units (95% CI 0.3 to 0.8), respectively. Mean age of each study cohort inversely correlated with depression prevalence.
conclusionsDepression is common among axSpA patients and is associated with more severe disease activity and functional impairment. Identifying and managing depression should form part of their holistic care. Further longitudinal studies are needed to explore the impact of depression on treatment outcomes and axSpA treatment on symptoms of depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.